Among patients with unruptured brain arteriovenous malformation, medical management alone is superior to its combination with interventional therapy for prevention of death or symptomatic stroke in the long term.
Administration of DOAC in combination with an antiplatelet agent may reduce the risk for hemorrhagic and embolic events in patients with nonvalvular atrial fibrillation following carotid artery stenting.
Patients with chronic lower extremity artery disease treated with a more vs less intensive antithrombotic therapeutic regimen were found to be at lower risk for limb amputation, stroke, and revascularization.
Researchers explored the incidence, clinical characteristics, associated factors, and clinical outcomes of late cerebrovascular events >30- days after TAVR.
Carotid artery stenting performed with the double-layer Roadsaver stent and proximal protection using the Mo.Ma Ultra device was found to be associated withthe best outcomes, in terms of microembolic signals, in high-risk patients with lipid-rich plaques.
The duration of carotid blood flow reversal during transcarotid artery revascularization for carotid bifurcation stenosis was not found to affect the rate of stroke, myocardial infarction, or death.
For young adults with supratentorial intracerebral hemorrhage (ICH), functional outcomes are improved with black and Hispanic versus white race/ethnicity.
